Citation Impact
Citing Papers
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
2009
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
2008
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
2002 Standout
Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota
2012 StandoutScience
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
2007 StandoutScience
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
2004 Standout
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Inflammation and cancer
2002 StandoutNature
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
2006
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
Clinical translation of angiogenesis inhibitors
2002 Standout
EMT and Dissemination Precede Pancreatic Tumor Formation
2012 Standout
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
2002
Tumor angiogenesis: past, present and the near future
2000
New insights into role of microenvironment in multiple myeloma
2000
Multiple Myeloma
2004
Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma
2003
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Angiogenesis in cancer and other diseases
2000 StandoutNature
The biology of VEGF and its receptors
2003 Standout
Multiple myeloma
2000 Standout
Overweight, Obesity, and Mortality in a Large Prospective Cohort of Persons 50 to 71 Years Old
2006 Standout
Cancer genes and the pathways they control
2004 Standout
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
2009
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
2003
Protein degradation and protection against misfolded or damaged proteins
2003 StandoutNature
Angiogenesis-dependent diseases
2001
Drug repurposing: progress, challenges and recommendations
2018 Standout
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
2009
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
2006
Immunity, Inflammation, and Cancer
2010 Standout
Topiramate Use Does Not Reduce Flares of Inflammatory Bowel Disease
2014
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
2001
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Inflammation and cancer: back to Virchow?
2001 Standout
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
2007
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
Treatment of Relapsed/Refractory Multiple Myeloma
2009
TGFβ in Cancer
2008 Standout
Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomas
2001
Thalidomide in the Treatment of Relapsed Multiple Myeloma
2000
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials
2001
Thalidomide
2004
Exploiting drug-disease relationships for computational drug repositioning
2011
Drug Insight: thalidomide as a treatment for multiple myeloma
2005
Multiple myeloma: evolving genetic events and host interactions
2002
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
2007
Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy
2003
Tumor necrosis factor or tumor promoting factor?
2002
Treatment of Multiple Myeloma: A Comprehensive Review
2009
Sarcoidosis
2007 Standout
Cancer-related inflammation
2008 StandoutNature
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications
2001
The occurrence and significance of V gene mutations in B cell—Derived human malignancy
2001
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
2001
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
2006 Standout
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches
2001
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Alternative activation of macrophages
2003 Standout
Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
2009
Genetics and biology of pancreatic ductal adenocarcinoma
2006
Paraneoplastic syndromes of the spinal cord, nerve, and muscle
2000
The thalidomide saga
2007
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
2007
Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas
2007
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene.
2001
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
2001
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
2001
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
2001
Angiogenesis Research: Guidelines for Translation to Clinical Application
2001
Recent major improvement in long-term survival of younger patients with multiple myeloma
2007
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice
2007 StandoutNobel
Combinatorial patterns of somatic gene mutations in cancer
2008
Low-dose of thalidomide in the treatment of refractory myeloma.
2000
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
2010
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
2005
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
2007
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
2004
Multiple Myeloma
2010
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
2000
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
2000
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Thalidomide in multiple myeloma
2005
High expression of cereblon (CRBN ) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
2013
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
2005
Genetics and Cytogenetics of Multiple Myeloma
2004
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
2009
Foxp3 Expression in Pancreatic Carcinoma Cells as a Novel Mechanism of Immune Evasion in Cancer
2007
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
2001
Cancer Genome Landscapes
2013 StandoutScience
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice
2007
Multiple Myeloma
2011 Standout
Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003
2007
Genes Expressed in Human Tumor Endothelium
2000 StandoutScience
The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets
2020 Standout
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
2002 Standout
Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis
2012
Idiopathic Pulmonary Fibrosis
2018 Standout
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Dan Ayers being referenced
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
2001
Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
2002
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
2000
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
2000